Pharma finds a way to gain weight
In the second quarter it paid to be a leading obesity company. As for Covid, not so much.
Approaching datasets for big pharma
J&J moves FcRn towards a big new therapy area, while Bristol, Merck, Astrazeneca and Daiichi Sankyo await important oncology catalysts.
Black Diamond’s lung cancer pivot delivers
The company’s stock surges 236% on first data with its new EGFR project, so where’s the catch?
UCB leads the stale scale
Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.
Nkarta goes back to basics
After a hiatus Nkarta comes back with a new lymphodepletion regimen to boost its lead Car-NK therapy.